Breaking News, Collaborations & Alliances

Regulus Earns GSK Milestone

Regulus Therapeutics, Inc. achieved the initial milestone in its worldwide strategic alliance with GlaxoSmithKline to discover, develop and market novel microRNA-based therapeutics to treat inflammatory diseases.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Regulus Therapeutics, Inc. achieved the initial milestone in its worldwide strategic alliance with GlaxoSmithKline to discover, develop and market novel microRNA-based therapeutics to treat inflammatory diseases. The two companies are working to identify drugs directed at four different microRNA targets related to inflammatory disease. Regulus received an undisclosed payment for the first demonstration of pharmacological effect in immune cells by specific microRNA inhibition. “This milestone ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters